AG真人官方

STOCK TITAN

Renovaro SEC Filings

RENB NASDAQ

Welcome to our dedicated page for Renovaro SEC filings (Ticker: RENB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Decoding Renovaro Inc鈥檚 oncology pipeline, gene-modified cell therapies, and AI-based diagnostics inside a 10-K can feel like navigating an immunology textbook. Clinical endpoints, FDA timelines, and multi-year R&D costs sprawl across hundreds of pages, while Form 4 updates arrive moments after executives trade shares. For investors, the science behind these immunotherapies is demanding; the disclosures are just as complex.

Stock Titan simplifies the challenge. Our AI reviews every document the instant it posts to EDGAR, delivering clear takeaways in plain English. Open the Renovaro Inc annual report 10-K simplified to track cash runway, scroll through a Renovaro Inc quarterly earnings report 10-Q filing for enrollment numbers, read Renovaro Inc SEC filings explained simply across our dashboard, or scan a Renovaro Inc 8-K material events explained after a breakthrough trial result鈥攐ur platform surfaces the narrative that moves the stock.

Need speed? Receive Renovaro Inc Form 4 insider transactions real-time so you never miss management鈥檚 sentiment shifts. Want context? Dive into a Renovaro Inc earnings report filing analysis, compare segments, or examine a Renovaro Inc proxy statement executive compensation table. From understanding Renovaro Inc SEC documents with AI to following every Renovaro Inc insider trading Form 4 transactions and each Renovaro Inc executive stock transactions Form 4, you gain:

  • AI-powered summaries that turn biotech jargon into plain language
  • AG真人官方-time alerts for every filing type, including 10-K, 10-Q, 8-K, and Form 4
  • Side-by-side metrics to gauge pipeline progress quarter over quarter

With Stock Titan, complex disclosures become routine, freeing you to focus on decisive investment moves instead of document navigation.

Filing
Rhea-AI Summary

Renovaro Inc. (Nasdaq: RENB) filed an 8-K reporting the forthcoming resignation of Chairman Maurice van Tilburg. The Board was notified on 22 Jul 2025, and the resignation becomes effective 22 Aug 2025. The filing states the departure is driven by Mr. van Tilburg鈥檚 acceptance of a leadership role at an unrelated company and is not due to any disagreement with Renovaro regarding operations, policies, or practices.

The change is disclosed under Item 5.02 and no successor has yet been named. CEO David Weinstein signed the filing. While the orderly, conflict-free exit limits governance risk, the loss of an experienced board leader may create short-term uncertainty until a replacement is announced. Investors should watch for updates on board succession and any impact on strategic oversight.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
proxy
-
Filing
Rhea-AI Summary

Renovaro Inc. (Nasdaq: RENB) disclosed in an 8-K that it received a Nasdaq Listing Rule 5620(a) deficiency notice on 7 July 2025 for failing to hold its FY 2024 annual shareholder meeting within 12 months of the 30 June 2024 fiscal year-end.

The company has 45 calendar days to submit a remediation plan; if Nasdaq accepts it, Renovaro could receive an extension until 29 December 2025 to regain compliance. Until then, the stock will continue trading on Nasdaq. Failure to file an acceptable plan or to hold the meeting by the deadline could lead to delisting.

Management states it is 鈥渨orking diligently鈥� to prepare the plan and schedule the meeting 鈥渁s soon as practicable.鈥� No other operational or financial metrics were disclosed.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
Filing
Rhea-AI Summary

Renovaro Inc. (RENB) 鈥� Schedule 13D/A Amendment 21 reports updated beneficial ownership of insider William Anderson Wittekind.

  • Current Beneficial Ownership: 18,133,196 common shares, equal to 8.0 % of the class.
  • Voting/Dispositive Power: Sole power over 5,606,644 shares; shared power over 12,526,552 shares, including 12,438,431 shares held by spouse Serhat Gumrukcu (subject to a U.S. District Court writ of attachment) and 88,121 jointly-owned shares.
  • Ownership Structure: Direct holdings plus stakes through Weird Science LLC and six grantor retained annuity trusts under Wittekind鈥檚 sole control.
  • Dilution Effect: RENB disclosed it will issue 53.6 million shares upon conversion of convertible notes on or before 11 July 2025, lifting total shares outstanding from 172.1 million to roughly 225.7 million. This transaction reduces Wittekind鈥檚 ownership from 10.4 % (reported in Amendment 20) to 8.0 % without any sale of shares.
  • No Change in Intent: Items 4 and 6 state 鈥淣ot Applicable,鈥� indicating no current plans to acquire additional securities, seek board changes, or enter material agreements.
  • Regulatory & Legal Note: The spouse鈥檚 12.4 million RENB shares are encumbered by litigation (Estate of Gregory Davis v. Serhat Daniel Gumrukcu, writ of attachment dated 27 Oct 2023).

The filing keeps Wittekind above the 5 % reporting threshold, but the imminent note conversion materially increases RENB鈥檚 public float and dilutes all existing holders. Investors should monitor (1) completion of the 53.6 million-share issuance, (2) any future amendments that reflect additional percentage changes, and (3) litigation outcomes that could affect the voting or disposal rights over the encumbered shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other

FAQ

What is the current stock price of Renovaro (RENB)?

The current stock price of Renovaro (RENB) is $0.29 as of July 29, 2025.

What is the market cap of Renovaro (RENB)?

The market cap of Renovaro (RENB) is approximately 69.7M.

What is the primary focus of Renovaro Inc?

Renovaro Inc is focused on developing innovative immunotherapies to combat cancer and leveraging AI-based diagnostics for early detection and personalized treatment.

How does Renovaro Inc integrate technology into its operations?

The company integrates cutting-edge AI algorithms and multi-omic data analytics into its diagnostic platform, thereby enhancing early cancer detection and supporting precision medicine.

What are the main business segments of Renovaro Inc?

Renovaro Inc operates through two primary segments: one dedicated to immunotherapy innovations and another focused on AI-driven diagnostic technologies.

How does the company ensure its research is robust and effective?

Renovaro Inc collaborates with leading academic and clinical institutions, ensuring that its research is validated and benefits from multidisciplinary scientific expertise.

What role does personalized medicine play in Renovaro Inc鈥檚 strategy?

Personalized medicine is central to the company鈥檚 strategy, allowing for treatments tailored to an individual鈥檚 unique biological profile, thereby improving therapeutic outcomes.

How does the AI-based diagnostic platform work?

The platform utilizes advanced machine learning algorithms to analyze multi-modal and multi-omic data from non-invasive samples, aiming to detect cancer at its earliest stages.

What distinguishes Renovaro Inc in the competitive biopharmaceutical landscape?

Its unique integration of immunotherapy with AI-enhanced diagnostics and strong collaborative partnerships distinguishes Renovaro Inc as an innovative force in precision cancer care.

What types of cancers is Renovaro Inc targeting with its technologies?

While the company focuses broadly on oncology, it targets various complex cancers by applying its immunotherapy and diagnostic platforms to enhance early detection and customize treatment.
Renovaro

NASDAQ:RENB

RENB Rankings

RENB Stock Data

69.72M
90.75M
50.1%
13.71%
3.46%
Biotechnology
Pharmaceutical Preparations
United States
SUITE 906 LOS ANGELES